Eli Lilly (NYSE: LLY) Introduces Vials of Weight-Loss Drug Zepbound Starting at $399 Per Month
On Tuesday, Eli Lilly (NYSE: LLY) said it has begun selling vials of the lowest starter dose of its popular […]
NYSE: LLY
NHS Likely to Block Eli Lilly (NYSE: LLY) Alzheimer’s Treatment, The Telegraph Reports
Eli Lilly’s (NYSE: LLY) treatment for early Alzheimer’s is expected to be blocked for use by Britain’s National Health Service
NHS Likely to Block Eli Lilly (NYSE: LLY) Alzheimer’s Treatment, The Telegraph Reports Read More »
Doctors Face Hurdles in Securing Wegovy for Older Americans with Heart Disease
NEW YORK – Older Americans are having little success getting prescriptions for the weight-loss drug Wegovy covered by Medicare despite
Doctors Face Hurdles in Securing Wegovy for Older Americans with Heart Disease Read More »
Roche to Fast-track Anti-Obesity Drug Development to Compete with Rivals: FT Report
Swiss drugmaker Roche plans to accelerate the development of its anti-obesity drugs to challenge rivals like Eli Lilly (NYSE: LLY)
Roche to Fast-track Anti-Obesity Drug Development to Compete with Rivals: FT Report Read More »
Eli Lilly (NYSE: LLY) Secures FDA Approval for Alzheimer’s Drug
On Tuesday, the U.S. Food and Drug Administration approved Eli Lilly’s (NYSE: LLY) treatment for early Alzheimer’s, making it the
Eli Lilly (NYSE: LLY) Secures FDA Approval for Alzheimer’s Drug Read More »
Eli Lilly and Company (LLY) to Purchase DICE Therapeutics (DICE) for $2.4 Billion
Eli Lilly and Company (NYSE: LLY) has reached an agreement to buy DICE Therapeutics, Inc. (NASDAQ: DICE). Eli Lilly will
Eli Lilly and Company (LLY) to Purchase DICE Therapeutics (DICE) for $2.4 Billion Read More »